Sarepta (NASDAQ: SRPT) rumors are once again swirling, and shares are up 3% as a result. The company is often talked about as a possible candidate for a buyout because of its drug Eteplirsen, which has had incredible results treating Duchenne muscular dystrophy. The 3% jump today was due to a presentation by Vertex Pharmaceuticals (NASDAQ: VRTX) on its cystic fibrosis drug Kalydeco, which had several slides discussing Eteplirsen. Vertex has been mentioned in passing before as a possible interested party in Sarepta. Shares currently trade around $30 per share, but a recent upgrade from Piper Jaffray pegged the stock to go to anywhere between $60 and $80 in the short term, and possibly as high as $160.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.